Mettler-Toledo International (MTD) Q3 2024 earnings summary

Executive summary

• Q3 2024 sales grew 1% to $954.5M, led by Laboratory and Service segments, while Industrial and Food Retail lagged and China showed modest growth amid ongoing market softness.

• Adjusted EPS rose 4% to $10.21; reported EPS was $9.96, and net earnings increased 5% to $211.5M.

• Gross margin improved to 60% (+60 bps YoY), driven by favorable pricing and mix.

• Innovation and productivity initiatives, including new product launches like CytoDirect, support future growth.

• Market demand remains soft globally, especially in China and Industrial, with macroeconomic and geopolitical uncertainties persisting.

Financial highlights

• Q3 2024 net sales: $954.5M (+1% YoY); nine-month sales: $2.83B (flat to -1% YoY).

• Adjusted operating profit for Q3: $296.6M (flat YoY); adjusted operating margin: 31.1% (-30 bps YoY).

• Adjusted EPS for Q3: $10.21 (+4% YoY); reported EPS: $9.96 (vs. $9.21 last year); nine-month adjusted EPS: $28.74 (flat YoY).

• Gross margin for Q3: 60.0% (+60 bps YoY); nine-month gross margin: 59.6% (+40 bps YoY).

• Operating cash flow for nine months: $702.2M (vs. $684.4M in 2023); adjusted free cash flow: $671M (+7% per share YoY).

Outlook and guidance

• Q4 2024 local currency sales expected to grow ~8% (including 6% benefit from prior shipping delays); adjusted EPS guidance: $11.63–$11.78.

• Full-year 2024 local currency sales growth forecast at ~2%; adjusted EPS: $40.35–$40.50, up ~6%.

• 2025 guidance: local currency sales to grow ~3% (including 1.5% headwind from shipping delays); adjusted EPS: $41.85–$42.50 (+4–5%).

• Free cash flow expected at $850M in 2024 and $860M in 2025; share repurchases of $850M in 2024 and $875M in 2025.

• Currency headwinds expected to reduce 2024 adjusted EPS growth by ~2%.